クリングルファーマ(株)の貸借残高情報
| 主市場 | 業種 | 証券コード/EDINET | 英名称 |
|---|
| 東証GRT | 医薬品 | 4884/ - | - |
| 公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
|---|
| 2022/03/11 | 日証協 | 120,757株 | +22.4% | 100,300株 | +82.03% | 306,664株 | -8.94% | 26,700株 | -45.17% |
| 2022/03/04 | 日証協 | 98,657株 | +24.63% | 55,100株 | +199.46% | 336,767株 | +2.65% | 48,700株 | -30.92% |
| 2022/02/25 | 日証協 | 79,157株 | -10.51% | 18,400株 | +54.62% | 328,066株 | +9.22% | 70,501株 | +298.29% |
| 2022/02/18 | 日証協 | 88,457株 | -6.94% | 11,900株 | -63.16% | 300,368株 | +2.63% | 17,701株 | -18.43% |
| 2022/02/10 | 日証協 | 95,057株 | +20.39% | 32,300株 | -29.01% | 292,667株 | +6.67% | 21,700株 | -24.13% |
| 2022/02/04 | 日証協 | 78,957株 | +23.26% | 45,500株 | +15.78% | 274,366株 | +5.86% | 28,601株 | -20.33% |
| 2022/01/28 | 日証協 | 64,057株 | +20.05% | 39,300株 | +24.37% | 259,166株 | +4.43% | 35,900株 | +42.46% |
| 2022/01/21 | 日証協 | 53,357株 | +42.83% | 31,600株 | +9999.99% | 248,166株 | +5.84% | 25,200株 | +72.6% |
| 2022/01/14 | 日証協 | 37,357株 | -0.53% | 200株 | -98.06% | 234,466株 | +5.92% | 14,600株 | +17.74% |
| 2022/01/07 | 日証協 | 37,557株 | -10.49% | 10,300株 | -29.93% | 221,366株 | +21.12% | 12,400株 | -63.2% |
| 2021/12/30 | 日証協 | 41,957株 | 0% | 14,700株 | 0% | 182,766株 | 0% | 33,700株 | 0% |
| 2021/12/24 | 日証協 | 41,957株 | +24.29% | 14,700株 | -2.65% | 182,766株 | +9.01% | 33,700株 | +56.74% |
| 2021/12/17 | 日証協 | 33,757株 | -0.88% | 15,100株 | -6.21% | 167,666株 | +25.91% | 21,500株 | +97.25% |
| 2021/12/10 | 日証協 | 34,057株 | -2.57% | 16,100株 | +25.78% | 133,166株 | -11.97% | 10,900株 | -34.34% |
| 2021/12/03 | 日証協 | 34,957株 | +7.04% | 12,800株 | -9.86% | 151,266株 | -0.79% | 16,600株 | -58.4% |
| 2021/11/26 | 日証協 | 32,657株 | +9.38% | 14,200株 | 0% | 152,466株 | +29.14% | 39,900株 | +667.31% |
| 2021/11/19 | 日証協 | 29,857株 | 0% | 0株 | -100% | 118,066株 | -21.01% | 5,200株 | -85.1% |
| 2021/11/05 | 日証協 | 33,857株 | +14.16% | 4,300株 | +126.32% | 155,256株 | +1.44% | 6,400株 | -79.87% |
| 2021/10/29 | 日証協 | 29,657株 | -2.63% | 1,900株 | -51.28% | 153,056株 | +27.59% | 31,800株 | +72.73% |
※株式分割は考慮していませんのでご注意ください。
Page Top